Best Electric Utility Stocks To Buy For 2015

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of engineered product maker ESCO Technologies (NYSE: ESE  ) dropped 10% today after a disappointing earnings report.

So what: Net sales dropped 4.4% in the fiscal second quarter to $166.2 million, short of the $170.5 million estimate. Earnings per share after adjusting for non-operating charges were $0.28, still below the $0.34 estimate. �

Now what: The AMI market was blamed for the miss as customer delays have put pressure on revenue. Still, investors weren't giving the company a break, especially after earnings per share guidance came in at $1.60-$1.80, well below the $2.08 Wall Street expected. I'm not buying the discount today and need to see strong revenue and earnings growth before considering this stock.

Interested in more info on ESCO Technologies? Add it to your watchlist by clicking here.

Best Electric Utility Stocks To Buy For 2015: Euro FX(P)

Ecopetrol S.A. operates as an integrated oil company in Colombia, Peru, Brazil, and the U.S. Gulf Coast. The company engages in the exploration, development, and production of crude oil and natural gas. As of December 31, 2010, its proved reserves of crude oil and natural gas consisted of 1,714.0 million barrels of oil equivalent. The company also transports crude oil, motor fuels, fuel oil, and other refined products, as well as mixture of diesel and palm oil. It owns transportation network consisting of 3,003 kilometers of crude oil pipeline directly, as well as an additional 2,178 kilometers of crude oil pipeline with its business partners; and 3,017 kilometers of multi-purpose pipelines for transportation of refined products from refinery to wholesale distribution points. As of the above date, Ecopetrol S.A. owned 58 stations with a nominal storage capacity of 19 million barrels of crude oil and 6 million barrels of refined products. In addition, the company owns and o perates refineries that produce a range of refined products, including gasoline, diesel, kerosene, jet fuel, aviation fuel, liquefied petroleum gas, sulfur, heavy fuel oils, motor fuels, and petrochemicals, including paraffin waxes, lube base oils, low-density polyethylene, aromatics, asphalts, alkylates, cyclohexane and aliphatic solvents, and refinery grade propylene, as well as provides industrial services to third parties. Further, it markets various refined and feed stock products, including regular and high octane gasoline, diesel fuel, jet fuel, natural gas, and petrochemical products. The company was formerly known as Empresa Colombiana de Petroleos and changed its name to Ecopetrol S.A. in June 2003. Ecopetrol S.A. was founded in 1948 and is based in Bogota, Colombia.

Advisors' Opinion:

• [By Rick Munarriz]

  Apple is at the wrong end of this trend, and that's not a pretty place to be. Think about music. Apple's riding the wrong horse there. At a time when Pandora (NYSE: P  ) usage is exploding -- active listeners are up 36% to 69.5 million -- Apple's emphasis on playback and digital purchases are out of touch. iPod sales have fallen sharply over the past two years, and iTunes Music Store sales have slowed to a crawl.

• [By WALLSTCHEATSHEET]

  Pandora is an Internet radio company that attempts to match listeners with their preferences in order to discover music they love. The company has just revealed who the new CEO of the company will be. The stock has been rising higher in recent quarters and is now trading at highs for the year. Over the last four quarters, earnings have been mixed while revenues have been rising, however, investors have expected more from the company. Relative to its peers and sector, Pandora has been a year-to-date performance leader. Look for Pandora to continue to OUTPERFORM.

Best Electric Utility Stocks To Buy For 2015: QAD Inc. (QADB)

QAD Inc. provides enterprise software applications, and related services and support for manufacturing companies worldwide. The company offers QAD Enterprise Applications, an integrated suite of software applications, which support the business processes. Its QAD Enterprise Applications include suites, such as QAD Financials to manage and control fiscal business processes at various levels; QAD Customer Management suite for manufacturers to acquire new customers and retain customers through service and support; QAD Manufacturing that offers solutions in the areas of planning and scheduling, cost management, material control, shop floor control, and reporting in various mixed-mode manufacturing environments; and QAD Supply Chain that fulfills materials planning and logistics requirements. The QAD Enterprise Applications also comprise QAD Service and Support product suite that handles service calls, manages service queues, and organizes mobile field resources, as well as pro vides project management support; QAD Enterprise Asset Management for managing assets from inception through operations and replacement; QAD Supply Chain Execution that provides capabilities to manage execution throughout a company�s supply chain; QAD Analytics that helps customers in analyses, decision-making, and performance management; and QAD QXtend toolset for open interoperability. The company also provides customer support and professional services. In addition, it operates QAD Store that enables customers to obtain information and to access updated software and add-on products. It serves automotive, consumer products, food and beverage, high technology, industrial products, and life sciences industries. The company sells its products directly; and through distributors and sales agents. QAD Inc. was founded in 1979 and is headquartered in Santa Barbara, California.

Advisors' Opinion:

• [By Lisa Levin]

  QAD (NASDAQ: QADB) shares gained 4.23% to reach a new 52-week high of $18.00 on Q4 results.

  McEwen Mining (NYSE: MUX) shares rose 5.93% to touch a new 52-week high of $3.72 after the company reported 4 updated reserve & resource estimate at the San Jose mine in Argentina.

Top 10 Integrated Utility Stocks To Buy Right Now: Helen of Troy Limited(HELE)

Helen of Troy Limited, together with its subsidiaries, engages in the design, development, import, marketing, and distribution of brand-name consumer products primarily in the United States and Canada, as well as in Europe, Asia, and Latin America. It operates in three segments: Personal Care, Housewares, and Healthcare/Home Environment. The Personal Care segment offers hair dryers, straighteners, curling irons, hair setters, shavers, mirrors, hot air brushes, home hair clippers and trimmers, paraffin baths, massage cushions, footbaths, body massagers, brushes, combs, hair accessories, liquid and aerosol hair styling products, men?s fragrances, men?s and women?s antiperspirants and deodorants, liquid and bar soaps, shampoos, conditioners, hair treatments, foot powder, body powder, and skin care products. The Housewares segment provides kitchen tools, cutlery, bar and wine accessories, household cleaning tools, food storage containers, tea kettles, trash cans, storage an d organization products, hand tools, gardening tools, kitchen mitts and trivets, barbeque tools, and rechargeable lighting products, as well as baby and toddler care products, including convertible high chair. The Healthcare/Home Environment segment offers humidifiers, de-humidifiers, vaporizers, thermometers, air purifiers, fans, portable heaters, heating pads, and electronic mosquito traps. The company sells its products primarily through mass merchandisers, drugstore chains, warehouse clubs, home improvement stores, catalogs, grocery stores, specialty stores, beauty supply retailers, e-commerce retailers, wholesalers, and various types of distributors, as well as directly online to end user consumers. Helen of Troy Limited was founded in 1968 and is based in Hamilton, Bermuda.

Advisors' Opinion:

• [By Monica Gerson]

  Helen of Troy (NASDAQ: HELE) is estimated to post its Q2 earnings at $0.72 per share on revenue of $292.15 million.

  Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

• [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

  Helen of Troy Ltd.(HELE) said it expects to buy back about $246 million of its shares through a Dutch auction tender offer that allowed the personal-care company to repurchase up to $300 million in stock. The company, whose products include OXO kitchen tools and Brut After Shave, said it expects to acquire about 3.7 million shares at $66.50 a share, the high end of its offering range.

• [By Wallace Witkowski]

  Helen of Troy Ltd (HELE) �shares rose 1.3% to $49.20 on light volume after reporting third-quarter earnings of $1.16 a share on revenue of $380.7 million. Analysts had forecast earnings of $1.09 a share on revenue of $378.9 million.

• [By Canadian Value]

  NEW YORK, Feb. 4, 2014 /PRNewswire/ -- Sachem Head Capital Management today sent a letter to the Board of Directors of leading consumer goods company Helen of Troy Limited (HELE). In the letter, Sachem Head outlines its belief that Helen of Troy shares are materially undervalued, highlighting the Board's apparent unwillingness to respond to recent inquiries regarding potential strategic combinations, and recommending actions for the Board of Directors to undertake to maximize value for the shareholders, including a thorough and legitimate review of strategic alternatives.

Best Electric Utility Stocks To Buy For 2015: Daimler AG (DDAIF)

Daimler AG (Daimler), incorporated on May 6, 1998, develops, manufactures, distributes and sells a range of automotive products, mainly passenger cars, trucks, vans and buses. It also provides financial and other services relating to its automotive businesses. The Company offers its automotive products and related financial services primarily in Western Europe and in the North American Free Trade Agreement (NAFTA) region, which consists of the United States, Canada and Mexico. During the year ended December 31, 2009, the Company derived approximately 46% of its revenue from sales in Western Europe and 21% from sales in the United States. It operates in five segments: Mercedes-Benz Cars, Daimler Trucks, Mercedes-Benz Vans, Daimler Buses and Daimler Financial Services. Its other business interests consist primarily of its equity investments in the European Aeronautic Defence and Space Company EADS N.V. (EADS) and in Tognum AG. In October 2009, Deutsche Bank AG completed the disposal of its interest in the Company. In June 2011, Daimler AG and Rolls-Royce Holdings PLC had secured around 94% interest in Tognum AG-DJ.

Mercedes-Benz Cars

Mercedes-Benz Cars designs, produces and sells Mercedes-Benz passenger cars, Maybach luxury sedans and smart micro compact passenger cars. During 2009, Mercedes-Benz Cars contributed approximately 51% of the Company�� revenue. The Company offers Mercedes-Benz passenger cars with a range of diesel and gasoline engines. Under the AMG brand, it offers versions of Mercedes-Benz vehicles with V8 or V12 engines in all classes, except in the A-, B-, R-, GL- and GLK-Classes. The Mercedes-Benz passenger car product range consists of S-Class, E-Class, C-Class, A-/B-Classes and ML-/R-/G-/GL-/GLK-Classes.

The S-Class is a line of luxury sedans, which are available in short and long wheelbase versions. In June 2009, the Company introduced a new generation of the S-Class sedans, including a hybrid version, the new S 400 BlueHYBRID. The S-Class sed! ans are complemented by the CL, a top-of-the-line two-door coupe, and the SL, a luxury roadster. The E-Class is a line of luxury sedans, coupes, convertibles and station wagons. It also offers the CLS, a four-door coupe based on the E-Class. The C-Class is a line of compact luxury sedans and station wagons. The CLC Sports Coupe and the SLK, a two-seat roadster, complement the C-Class product family.

The A-Class is a front wheel drive compact and the B-Class is a front wheel drive 4-door Compact Sports Tourer (CST). The Company does not offer the A- and B-Classes in the United States. The ML-Class is a line of sport utility vehicles with permanent all-wheel drive. The R-Class is a line of SUV Tourers, which is available in a short and a long wheelbase version. The GL-Class is a line of seven seat luxury sport utility vehicles. The GLK-Class is a line of compact sport utility vehicles. The G-Class is a line of cross country vehicles with permanent four-wheel drive that come in a short and a long wheelbase version, and as a convertible. Under the Maybach brand, the Company offers a line of luxury sedans with outstanding luxury, comfort, and individuality. Maybach sedans are available in a short and a long wheelbase version, including the Maybach 57S and 62S as sportier variations. The smart brand represents a micro compact car concept. It offers two models, the smart fortwo coupe and the smart fortwo cabrio.

Daimler Trucks

Daimler Trucks manufactures and sells trucks and specialty vehicles under the brand names Mercedes-Benz, Freightliner, Western Star, Thomas Built Buses and Fuso. During 2009, Daimler Trucks contributed approximately 21% of its revenue. During 2009, the Company ceased production of trucks under the Sterling brand name. The Company�� European Mercedes-Benz truck lines consist of the Actros and the Axor in the heavy-duty category, the Atego in the medium-duty category, and the specialty vehicles Econic and Zetros. The Unimog, a four-wheel drive ve! hicle for! special purpose applications, complements the line-up. In Turkey and Brazil, it manufactures heavy-duty and medium-duty trucks for the respective local and certain export markets. Its Mercedes-Benz trucks range from 6 metric tons gross vehicle weight (GVW) to 41 metric tons GVW.

The Company�� United States subsidiary, Daimler Trucks North America LLC, manufactures trucks and buses (based on truck chassis) in Classes 3 through 8 (from 9,000 lbs. GVW to 160,000 lbs. GVW) and sells them under the Freightliner, Western Star, and Thomas Built Buses brand names, primarily in the NAFTA region. It also manufactures chassis for trucks, buses, walk-in vans and motor homes in Classes 3 through 7 (from 10,000 lbs. GVW to 33,000 lbs. GVW). During 2009, Freightliner introduced a new version of the Coronado, an on-highway truck. It Japan-based subsidiary, Mitsubishi Fuso Truck and Bus Corporation (MFTBC), offers a truck portfolio and several bus lines, primarily for the Japanese and other Asian markets. The line-up includes the Canter trucks (light-duty), the Fighter trucks (medium-duty) and the Super Great trucks (heavy-duty) and also certain bus models (Rosa and Aero). MFTBC also sells trucks in Africa, Australia, Europe, Latin America and the United States.

Mercedes-Benz Vans

Mercedes-Benz Vans designs, manufactures and sells vans under the brand names Mercedes-Benz and Freightliner. During 2009, Mercedes-Benz Vans contributed approximately 8% of its revenue. The Company offers three lines of Mercedes-Benz vans between 1.9 metric tons (t) and 7.5t gross vehicle weight (GVW): the Vario, the Vito/Viano and the Sprinter. In the NAFTA region it sells the Sprinter under the Freightliner brand name and, since January 1, 2010, also under the Mercedes-Benz brand name. As of December 31, 2009, subsidiaries of Chrysler Holding LLC sold the Sprinter in the United States under the Dodge and Freightliner brand names, and in Canada under the Dodge brand name.

Daimler Buse! s

!

Daimler Buses is a global supplier in the worldwide bus market. During 2009, Daimler Buses contributed approximately 5% of the Company�� revenue. Its product portfolio includes city buses, coaches, intercity buses, midi buses and bus chassis. It sells complete buses under the Mercedes-Benz and Setra brands in Europe, under the Mercedes-Benz brand name in Mexico, and under the Setra and Orion brand names in the United States and Canada. In addition, Daimler Buses produces and sells worldwide a range of bus chassis under the brand name Mercedes-Benz.

Daimler Financial Services

The Company�� financial services activities contributed approximately 15% of its revenue during 2009. It consists principally of financing and leasing services supporting its Mercedes-Benz and other vehicle businesses. The financial services the Company offers consist mainly of customized financing and leasing packages for its retail and wholesale customers in the automotive sector. It also provides financing to its dealers for vehicle inventory and property, plant and equipment purchases, and it offers insurance brokerage and fleet management services, including dealer property and casualty insurance. In Germany, the Company operates a licensed bank, the Mercedes-Benz Bank. The Mercedes-Benz Bank offers financial services to its customers and employees in Germany. These services include leasing and sales financing services, car savings plans, credit cards and demand deposit accounts. In addition, the Mercedes-Benz Bank operates branches in Great Britain and Spain to refinance the local dealer portfolios.

The Company competes with BMW, Volkswagen, Fiat, Ford, General Motors, PSA, Renault, Tata Motors, Toyota, Honda, Nissan, Suzuki, Scania, Iveco, Volvo, DAF, Navistar International, Paccar, Hino, Isuzu, MAN Commercial Vehicles, Irisbus and Agrale.

Advisors' Opinion:

• [By Associated Press]

  According to the ACEA, in the first three months of 2013 General Motors saw sales drop 13 percent, PSA Peugeot sales were down 15 percent, Ford was down by 20 percent, Toyota (NYSE: TM  ) 18 percent, and Fiat 9 percent. In the premium market, which had continued to sell well as the mass market slumped, manufacturers were starting to feel the pinch. BMW was down a slight 0.9 percent while Daimler (NASDAQOTH: DDAIF  ) rose 0.2 percent.

• [By John Rosevear]

  Audi had about 29% of the Chinese luxury-car market last year. Together with German archrivals BMW (NASDAQOTH: BAMXF  ) and Mercedes-Benz (NASDAQOTH: DDAIF  ) , German brands account for about three-quarters of China's luxury-vehicle sales.

• [By Jonathan Yates]

  Luxury goods companies such as Ralph Lauren (NYSE: RL), Michael Kors (NASDAQ: KORS) and Mercedes Benz (OTC: DDAIF) count on China for increasing sales. And among the most desired items by Chinese consumers are handbags and other accessories from Coach Inc (NYSE: COH).

• [By John Rosevear]

  This past week, German automaker Daimler (NASDAQOTH: DDAIF  ) announced a new deal with Aston Martin, the tiny British company famous for its line of sleek -- and expensive -- sports cars.

Best Electric Utility Stocks To Buy For 2015: GFI Group Inc. (GFIG)

GFI Group Inc. provides wholesale brokerage, clearing, electronic execution, and trading support products for financial markets. The company offers brokerage and trade execution services, clearing services, market data and trading platform, and other software products to institutional customers. The company provides brokerage services in fixed income derivatives, bond instruments, and other related products; financial instruments, including foreign exchange options, exotic options, non-U.S. Dollar interest rate swaps and options, repurchase agreements, forward and non-deliverable forward contracts, and government and municipal bond options; cash-based and derivative equity products, such as the U.S. domestic and international equity stocks, global depositary receipts, American depositary receipts, and equity derivatives; and cash-based and derivative commodity, and energy products comprising oil, natural gas, biofuel, electricity, wet and dry freight derivatives, dry physi cal freight, precious metals, coal, property derivatives, emissions, ethanol, and soft commodities. It also offers clearing, brokerage, settlement, and back-office services to proprietary traders, brokers, market makers, and hedge funds; provides capital to start-up trading groups, small hedge funds, market-makers, and individual traders; licenses multi-asset class electronic trading and order management software to brokers, exchanges, and traders in the commodities, fixed income, currencies, and equities markets; and offers FENICS Professional, a suite of price discovery, price distribution, trading, risk management, and straight-through processing components. The company primarily serves investment and commercial banks, large corporations, asset managers, insurance companies, hedge funds, and proprietary trading firms in the Americas; Europe, the Middle East, and Africa; and Asia. GFI Group Inc. was founded in 1987 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Jayson Derrick]

  CME Group (NYSE: CME) has agreed to acquire GFI Group (NASDAQ: GFIG) for $4.55 per share and will immediately sell it's wholesale brokerage and clearing business back to a group led by GFI Management. CME will retain GFI Group's Trayport which provides trading software in the European energy markets as well as FENICS, a provider of price discovery, analytics, risk-management and workflow connectivity services for over the counter foreign exchange options markets. Shares of CME Group gained 0.44 percent, closing at $75.83 while shares of GFI Group surged to new 52-week highs of $4.50 before closing the day at $4.47, up 43.73 percent.

Best Electric Utility Stocks To Buy For 2015: lime energy co.(LIME)

Lime Energy Co. provides energy engineering, consulting, and implementation solutions to the commercial, industrial, utilities, governmental, and energy services markets in the United States. The company?s energy efficiency solutions enable its clients to reduce energy-related expenditures and the impact of their energy use on the environment. Its services include energy consulting, integrated energy engineering, and multi-measure project development and implementation; mechanical/electrical upgrade services; water conservation; weatherization; and renewables across a range of facilities, including office buildings, manufacturing plants, retail sites, mixed use complexes, and large government sites. The company?s energy consulting and technical services comprise utility program management and implementation, energy project development, energy engineering, consulting, and planning. Lime Energy Co. also provides energy asset development and management services comprising p roject feasibility and technology assessment; sourcing, qualifying, and structuring investment opportunities; project financing; design and construction process management; and asset management. Its customers include commercial and industrial businesses, property owners and managers, utilities, energy service companies, government entities, and educational institutions. The company was formerly known as Electric City Corp. and changed its name to Lime Energy Co. in September 2006. Lime Energy Co. was founded in 1980 and is headquartered in Huntersville, North Carolina.

Advisors' Opinion:

• [By Lauren Pollock]

  Lime Energy Co.(LIME) fired Chief Executive John O’Rourke while simultaneously promoting President and Chief Operating Officer Adam Procell to the top post.

• [By CRWE]

  Lime Energy Co. (NASDAQ:LIME) reported their addition to NSTAR�� Municipal Program, which incentivizes municipalities to implement energy efficiency measures. The pre-selection of energy efficiency contractors is intended to streamline the procurement process for the municipalities that NSTAR currently serves.

Best Electric Utility Stocks To Buy For 2015: Osiris Therapeutics Inc.(OSIR)

Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Advisors' Opinion:

• [By Lauren Pollock]

  Osiris Therapeutics Inc.(OSIR) said Friday a proposed ruling from the Centers for Medicare and Medicaid Services won’t immediately affect reimbursements for its Grafix stem-cell product. The regenerative medicine company said Grafix will maintain its current reimbursement status — also called transitional pass-through status — potentially through late 2015.

• [By Alexander Maxwell]

  One of the companies attempting to develop a better treatment for chronic diabetic foot ulcers is Osiris Therapeutics� (NASDAQ: OSIR  ) . Earlier this month, Osiris shares more than doubled as the company announced positive data for its CDFU drug Grafix. The study results were very impressive to say the least; the study was stopped early due to the overwhelming efficacy exhibited by the treatment. A main highlight is the fact that 62% of Grafix patients had their wound closed at 12 weeks, compared to only 21% of patients using conventional methods. Clearly, the efficacy in this endpoint was overwhelming. Grafix also achieved all of the secondary endpoints for the trial, and more importantly demonstrated a relatively benign safety record.�

• [By Maxx Chatsko]

  Additionally, stem cell therapies have remained elusive as the industry's ultimate Holy Grail. Osiris (NASDAQ: OSIR  ) received Canadian approval for the world's first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.

Best Electric Utility Stocks To Buy For 2015: ImmunoCellular Therapeutics Ltd (IMUC)

ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.

The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.

Advisors' Opinion:

• [By Lauren Pollock]

  ImmunoCellular Therapeutics Ltd.(IMUC) said its leading product candidate, a dendritic cell-based vaccine for brain cancer, didn’t show a statistically significant advantage in overall survival in a Phase II study. In a research note, Maxim Group said it is pushing its EU approval date target to 2019 and lowered its estimate on the stock to $12 a share from $18 a share. The stock plunged 62% to $1.04 premarket.

• [By Smith On Stocks]

  Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.

• [By Wallace Witkowski]

  Shares of ImmunoCellular (IMUC) �jumped after the drug developer said data on a mid-stage brain cancer drug study were looking encouraging.

• [By Monica Gerson]

  ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.

  Posted-In: market losersNews Movers & Shakers Intraday Update Markets

Best Electric Utility Stocks To Buy For 2015: OncoGenex Pharmaceuticals Inc.(OGXI)

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The company?s clinical stage products include Custirsen, a phase III clinical stage product for treatment in men with metastatic castrate-resistant prostate cancer; OGX-427, which is in phase II clinical development stage is designed to inhibit heat shock protein 27; and SN2310 that completed phase I stage of clinical development is designed to evaluate safety in patients with advanced cancer. Its pre clinical stage products include GX-225 that is focused on reducing the production of IGFBP-2 and IGFBP-5; and CSP-9222, lead compound from a family of caspase activators. OncoGenex Pharmaceuticals, Inc. is based in Bothell, Washington.

Advisors' Opinion:

• [By John McCamant]

  2014 is shaping up to be the most important year for OncoGenex Pharmaceuticals (OGXI), and, we believe, it can very well represent a major inflection point for the company with positive Synergy results.

• [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]

  Teva Pharmaceutical Industries Ltd.(TEVA) and OncoGenex Pharmaceuticals Inc.(OGXI) said their experimental drug for hard-to-treat cases of prostate cancer didn’t result in statistically significant improvement in overall survival in a Phase 3 study. OncoGenex shares dropped 48% to $5 premarket.